We are using CRISPR technologies to make new genetic medicines that prevent and treat radiation sickness.
Acute radiation syndrome (ARS) affects the gut and/or bone marrow, poses a serious health risk to warfighters and first responders, and creates a dose-limiting problem in radiation therapy for cancer patients. Our goal is to create genetic medicines that prevent and treat ARS.
Taking advantage of tremendous advances in functional genomics such as genome-wide CRISPRi/a pooled screens, we will find genes that modulate radiation resistance in human cells and organoids. Simultaneously, we are investigating the most effective methods of CRISPRi/a, and optimizing nanoparticle delivery. Ultimately, we aim to combine these lines of research to find ways of temporarily and reversibly modifying gene expression to provide single-dose prophylaxis and treatment for radiation exposure.
Share this project: